{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:28:39Z","timestamp":1791264519797,"version":"4.1.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.2515\/therapie\/2010051","type":"journal-article","created":{"date-parts":[[2010,12,10]],"date-time":"2010-12-10T13:35:52Z","timestamp":1291988152000},"page":"447-458","source":"Crossref","is-referenced-by-count":10,"title":["Hyperglyc\u00e9mies d\u2019origine m\u00e9dicamenteuse : \u00e9tude dans la Base Nationale Fran\u00e7aise de PharmacoVigilance (BNPV)"],"prefix":"10.1016","volume":"65","author":[{"given":"Leila","family":"Chebane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Tavassoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haleh","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Jean-LouisMontastruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.2515\/therapie\/2010051_bb0005","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2165\/00002018-199615020-00005","article-title":"Drug-induced disorders of glucose metabolism","volume":"15","author":"Chan","year":"1996","journal-title":"Mechanisms and management. Drug Saf"},{"key":"10.2515\/therapie\/2010051_bb0010","first-page":"185","article-title":"M\u00e9dicaments qui augmentent la glyc\u00e9mie","volume":"302","author":"Auteurs anonymes","year":"2008","journal-title":"Rev Prescrire"},{"key":"10.2515\/therapie\/2010051_bb0015","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-118-7-199304010-00008","article-title":"Drug-induced disorders of glucose tolerance","volume":"118","author":"Pandit","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.2515\/therapie\/2010051_bb0020","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.286.16.1945","article-title":"Drug-induced hyperglycemia","volume":"286","author":"Luna","year":"2001","journal-title":"JAMA"},{"key":"10.2515\/therapie\/2010051_bb0025","first-page":"111","article-title":"Unexpected or toxic drug reaction assessment (imputation)","volume":"40","author":"B\u00e9gaud","year":"1985","journal-title":"Therapie"},{"key":"10.2515\/therapie\/2010051_bb0030","first-page":"557","article-title":"La banque de cas du syst\u00e8me fran\u00e7ais de Pharmacovigilance : quelques exemples d\u2019exploitation","volume":"50","author":"Moore","year":"1995","journal-title":"Th\u00e9rapie"},{"key":"10.2515\/therapie\/2010051_bb0035","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2010051_bb0040","unstructured":"http:\/\/www.theriaque.org."},{"key":"10.2515\/therapie\/2010051_bb0045","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/00002018-200326050-00001","article-title":"Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions","volume":"26","author":"Van Puijenbroek","year":"2003","journal-title":"Drug Saf"},{"key":"10.2515\/therapie\/2010051_bb0050","first-page":"523","article-title":"Pharmacologie des conceptions fondamentaux aux applications th\u00e9rapeutiques","author":"Schorderet","year":"1998","journal-title":"R\u00e9gulateurs de la glyc\u00e9mie. \u00c9ditions Frison-Roche"},{"key":"10.2515\/therapie\/2010051_bb0055","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1476-5381.1994.tb14817.x","article-title":"Effect of lithium on plasma glucose, insulin and glucagon in normal and streptozotocin-diabetic rats: role of glucagon in the hyperglycaemic response","volume":"111","author":"Hermida","year":"1994","journal-title":"Br J Pharmacol"},{"key":"10.2515\/therapie\/2010051_bb0060","first-page":"623","article-title":"Lithium in diabetes mellitus: a paradoxical response","volume":"39","author":"Waziri","year":"1978","journal-title":"J Clin Psychiatry"},{"key":"10.2515\/therapie\/2010051_bb0065","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1530\/acta.0.1110342","article-title":"Blocking effect of naloxone, dihydroergotamine and adrenalectomy in lithium-induced hyperglycaemia and glucose intolerance in the rat","volume":"111","author":"Fontela","year":"1986","journal-title":"Acta Endocrinol"},{"key":"10.2515\/therapie\/2010051_bb0070","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1530\/acta.0.1230405","article-title":"Influence of danazol and goserelin on insulin and glucagon in non-obese women with endometriosis","volume":"123","author":"Golland","year":"1990","journal-title":"Acta Endocrinol"},{"key":"10.2515\/therapie\/2010051_bb0075","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1042\/cs0820211","article-title":"Danazol induces resistance to both insulin and glucagon in young women","volume":"82","author":"Bruce","year":"1992","journal-title":"Clin Sci"},{"key":"10.2515\/therapie\/2010051_bb0080","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1365-2362.1995.tb01971.x","article-title":"Effect of danazol-induced chronic hyperglucagonaemia on glucose tolerance and turnover","volume":"25","author":"Kotzmann","year":"1995","journal-title":"Eur J Clin Invest"},{"key":"10.2515\/therapie\/2010051_bb0085","first-page":"160","article-title":"Decreased sensitivity to insulin during treatment with danazol in women with endometriosis","volume":"24","author":"Matalliotakis","year":"1997","journal-title":"Clin Exp Obstet Gynecol"},{"key":"10.2515\/therapie\/2010051_bb0090","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1136\/bmj.291.6503.1155","article-title":"Treatment with danazol and plasma glucagon concentration","volume":"291","author":"Williams","year":"1985","journal-title":"Br Med J"},{"key":"10.2515\/therapie\/2010051_bb0095","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.taap.2004.02.009","article-title":"The potential biological mechanisms of arsenic-induced diabetes mellitus","volume":"197","author":"Tseng","year":"2004","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.2515\/therapie\/2010051_bb0100","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.taap.2005.11.015","article-title":"Sodium arsenite impairs insulin secretion and transcription in pancreatic beta-cells","volume":"214","author":"D\u00edaz-Villase\u00f1or","year":"2006","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.2515\/therapie\/2010051_bb0105","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.taap.2003.10.026","article-title":"Inhibition of insulin-dependent glucose uptake by trivalent arsenicals: possible mechanism of arsenicinduced diabetes","volume":"198","author":"Walton","year":"2004","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.2515\/therapie\/2010051_bb0110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00041552-199210000-00005","article-title":"ATP-sensitive potassium channels in physiology, pathophysiology, and pharmacology","volume":"1","author":"Misler","year":"1992","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.2515\/therapie\/2010051_bb0115","first-page":"691","article-title":"Do KCa channels and carbonic anhydrase play a role in thiazide-induced hyperglycaemia?","volume":"9","author":"Pickkers","year":"1995","journal-title":"J Hum Hypertens"},{"key":"10.2515\/therapie\/2010051_bb0120","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/j.1476-5381.1993.tb13969.x","article-title":"Inhibition by hydrochlorothiazide of insulin release and calcium influx in mouse pancreatic beta-cells","volume":"110","author":"Sandstr\u00f6m","year":"1993","journal-title":"Br J Pharmacol"},{"key":"10.2515\/therapie\/2010051_bb0125","first-page":"E591","article-title":"Furosemide reduces insulin release by inhibition of Cl- and Ca2+ fluxes in beta-cells","volume":"255","author":"Sandstr\u00f6m","year":"1988","journal-title":"Am J Physiol"},{"key":"10.2515\/therapie\/2010051_bb0130","doi-asserted-by":"crossref","first-page":"862","DOI":"10.2337\/diabetes.54.3.862","article-title":"Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebocontrolled study of olanzapine and risperidone in dogs","volume":"54","author":"Ader","year":"2005","journal-title":"Diabetes"},{"key":"10.2515\/therapie\/2010051_bb0135","first-page":"30","article-title":"Hyperglycemia associated with the use of atypical antipsychotics","volume":"62","author":"Lindenmayer","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.2515\/therapie\/2010051_bb0140","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00213-003-1529-4","article-title":"Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses","volume":"170","author":"Melkersson","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.2515\/therapie\/2010051_bb0145","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archpsyc.59.4.337","article-title":"Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia","volume":"59","author":"Newcomer","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"10.2515\/therapie\/2010051_bb0150","first-page":"26","article-title":"Insulin resistance in kidney allograft recipients treated with calcineurin inhibitors","volume":"12","author":"Wyzga\u015f","year":"2007","journal-title":"Ann Transplant"},{"key":"10.2515\/therapie\/2010051_bb0155","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2131\/jts.19.2_61","article-title":"Mechanism of FK506-induced glucose intolerance in rats","volume":"19","author":"Hirano","year":"1994","journal-title":"J Toxicol Sci"},{"key":"10.2515\/therapie\/2010051_bb0160","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/00007890-199204000-00033","article-title":"Morphological and functional changes of isolets of Langerhans in FK506-treated rats","volume":"53","author":"Hirano","year":"1992","journal-title":"Transplantation"},{"key":"10.2515\/therapie\/2010051_bb0165","doi-asserted-by":"crossref","first-page":"E365","DOI":"10.1152\/ajpendo.00390.2004","article-title":"Tacrolimus suppresses glucoseinduced insulin release from pancreatic islets by reducing glucokinase activity","volume":"288","author":"Radu","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.2515\/therapie\/2010051_bb0170","first-page":"489","article-title":"Pharmacologie des concepts fondamentaux aux applications th\u00e9rapeutiques","author":"Schorderet","year":"1998","journal-title":"St\u00e9ro\u00efdes corticosurr\u00e9naliens. \u00c9ditions Frison-Roche"},{"key":"10.2515\/therapie\/2010051_bb0175","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/COH.0b013e3283139134","article-title":"HIV protease inhibitors and insulin resistance: lessons from in vitro, rodent and healthy human volunteer models","volume":"3","author":"Hruz","year":"2008","journal-title":"Curr Opin HIV AIDS"},{"key":"10.2515\/therapie\/2010051_bb0180","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1152\/ajpendo.00167.2007","article-title":"HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus","volume":"294","author":"Carper","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.2515\/therapie\/2010051_bb0185","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1097\/01.aids.0000181011.62385.91","article-title":"Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study","volume":"19","author":"Brown","year":"2005","journal-title":"AIDS"},{"key":"10.2515\/therapie\/2010051_bb0190","first-page":"53","article-title":"Current HIV therapeutics: mechanistic and chemical determinants of toxicity","volume":"12","author":"Chiao","year":"2009","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.2515\/therapie\/2010051_bb0195","first-page":"23","article-title":"Side effects of antiretroviral therapy","volume":"108","author":"Teodor","year":"2004","journal-title":"Rev Med Chir Soc Med Nat Iasi"},{"key":"10.2515\/therapie\/2010051_bb0200","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/hep.22665","article-title":"Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy","volume":"49","author":"Ingiliz","year":"2009","journal-title":"Hepatology"},{"key":"10.2515\/therapie\/2010051_bb0205","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/15563659609013771","article-title":"Hypoglycemia associated with phenytoin intoxication","volume":"34","author":"Manto","year":"1996","journal-title":"J Toxicol Clin Toxicol"},{"key":"10.2515\/therapie\/2010051_bb0210","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1464-5491.1991.tb01539.x","article-title":"Phenytoin-induced insulin insensitivity","volume":"8","author":"Al-Rubeaan","year":"1991","journal-title":"Diabet Med"},{"key":"10.2515\/therapie\/2010051_bb0215","first-page":"74","article-title":"Studies on the hyperglycemic effect of diphenylhydantoin in normal golden hamsters","volume":"6","author":"Tamburrano","year":"1976","journal-title":"Horm Metab Res"},{"key":"10.2515\/therapie\/2010051_bb0220","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1172\/JCI106413","article-title":"The in vitro inhibition of insulin secretion by diphenylhydantoin","volume":"49","author":"Kizer","year":"1970","journal-title":"J Clin Invest"},{"key":"10.2515\/therapie\/2010051_bb0225","first-page":"29","article-title":"Effects of beta-blocking agents on insulin secretion and glucose disposal","volume":"22","author":"Wicklmayr","year":"1990","journal-title":"Horm Metab Res Suppl"},{"key":"10.2515\/therapie\/2010051_bb0230","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1358\/mf.2008.30.10.1316824","article-title":"Influence of diabetes on liver injury induced by antitubercular drugs and on silymarin hepatoprotection in rats","volume":"30","author":"Srivastava","year":"2008","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.2515\/therapie\/2010051_bb0235","first-page":"487","article-title":"Risk factors of side effects of antituberculosis drugs","volume":"84","author":"El Gharbi","year":"2006","journal-title":"Tunis Med"},{"key":"10.2515\/therapie\/2010051_bb0240","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1172\/JCI115145","article-title":"Effect of nicotinic acidinduced insulin resistance on pancreatic B cell function in normal and streptozocin-treated baboons","volume":"87","author":"Mc Culloch","year":"1991","journal-title":"J Clin Invest"},{"key":"10.2515\/therapie\/2010051_bb0245","doi-asserted-by":"crossref","first-page":"562","DOI":"10.2337\/diab.38.5.562","article-title":"Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinic acid- induced insulin resistance","volume":"38","author":"Kahn","year":"1989","journal-title":"Diabetes"},{"key":"10.2515\/therapie\/2010051_bb0250","first-page":"1752","article-title":"Hyperglycemia and inhibition of glucose-induced insulin release in 6-aminonicotinamide treated rats","volume":"59","author":"Tanese","year":"1983","journal-title":"Nippon Naibunpi Gakkai Zasshi"},{"key":"10.2515\/therapie\/2010051_bb0255","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4158\/EP.15.2.153","article-title":"Type B insulin resistance developing during interferon-alpha therapy","volume":"15","author":"Daniel","year":"2009","journal-title":"Endocr Pract"},{"key":"10.2515\/therapie\/2010051_bb0260","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1001\/archinte.1993.00410170142014","article-title":"Severe reversible hyperglycemia as a consequence of niacin therapy","volume":"153","author":"Schwartz","year":"1993","journal-title":"Arch Intern Med"},{"key":"10.2515\/therapie\/2010051_bb0265","doi-asserted-by":"crossref","first-page":"22C","DOI":"10.1016\/j.amjcard.2006.11.018","article-title":"Safety considerations with niacin therapy","volume":"99","author":"Guyton","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.2515\/therapie\/2010051_bb0270","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00043426-198608010-00018","article-title":"Hyperglucagonemia in L-asparaginase induced diabetes mellitus","volume":"8","author":"Rao","year":"1986","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"10.2515\/therapie\/2010051_bb0275","first-page":"21","article-title":"M\u00e9dications cardio-vasculaires et respiratoires. Syst\u00e8me sympathique, agonistes, antagonistes (\u03b2-bloquants exclus)","author":"Montastruc","year":"1998","journal-title":"\u00c9ditions Hermann. \u00c9diteurs des sciences et des arts"},{"key":"10.2515\/therapie\/2010051_bb0280","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/S0140-6736(05)60074-8","article-title":"Protease inhibitors and adipocyte differentiation in cell culture","volume":"352","author":"Gagnon","year":"1998","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2010051_bb0285","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(98)03391-1","article-title":"Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance","volume":"351","author":"Carr","year":"1998","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2010051_bb0290","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.biochi.2004.12.007","article-title":"HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo","volume":"87","author":"Lagathu","year":"2005","journal-title":"Biochimie"},{"key":"10.2515\/therapie\/2010051_bb0295","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1210\/jc.2002-020795","article-title":"Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy","volume":"88","author":"Addy","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.2515\/therapie\/2010051_bb0300","doi-asserted-by":"crossref","first-page":"F63","DOI":"10.1097\/00002030-199907090-00001","article-title":"Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors","volume":"13","author":"Behrens","year":"1999","journal-title":"AIDS"},{"key":"10.2515\/therapie\/2010051_bb0305","first-page":"920","article-title":"Diabetic ketoacidosis in an HIV-infected patient undergoing antiretroviral therapy","volume":"168","author":"Holm","year":"2006","journal-title":"Ugeskr Laeger"},{"key":"10.2515\/therapie\/2010051_bb0310","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1086\/339866","article-title":"Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy","volume":"34","author":"Sav\u00e8s","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.2515\/therapie\/2010051_bb0315","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1046\/j.1525-1497.2002.10649.x","article-title":"Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly","volume":"17","author":"Blackburn","year":"2002","journal-title":"J Gen Intern Med"},{"key":"10.2515\/therapie\/2010051_bb0320","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2165\/00023210-200216020-00001","article-title":"Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?","volume":"16","author":"Henderson","year":"2002","journal-title":"CNS Drugs"},{"key":"10.2515\/therapie\/2010051_bb0325","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1176\/appi.ajp.160.2.290","article-title":"Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics","volume":"160","author":"Lindenmayer","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.2515\/therapie\/2010051_bb0330","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2165\/00003495-200464070-00003","article-title":"Adverse metabolic effects associated with atypical anti psychotics: literature review and clinical implications","volume":"64","author":"Melkersson","year":"2004","journal-title":"Drugs"},{"key":"10.2515\/therapie\/2010051_bb0335","first-page":"1","article-title":"Relative risk of glucose elevation during antipsychotic exposure in a Veterans Administration population","volume":"22","author":"Duncan","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"key":"10.2515\/therapie\/2010051_bb0340","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/10401230600801234","article-title":"Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies","volume":"18","author":"Ramaswamy","year":"2006","journal-title":"Ann Clin Psychiatry"},{"key":"10.2515\/therapie\/2010051_bb0345","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1176\/appi.ajp.161.9.1709","article-title":"Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications","volume":"161","author":"Leslie","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.2515\/therapie\/2010051_bb0350","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/10401230701844612","article-title":"Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004)","volume":"20","author":"Du Mouchel","year":"2008","journal-title":"Ann Clin Psychiatry"},{"key":"10.2515\/therapie\/2010051_bb0355","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2165\/00002018-200225150-00005","article-title":"Glucose intolerance with atypical antipsychotics","volume":"25","author":"Hedenmalm","year":"2002","journal-title":"Drug Saf"},{"key":"10.2515\/therapie\/2010051_bb0360","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/S0149-2918(03)80073-5","article-title":"Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders","volume":"25","author":"Gianfrancesco","year":"2003","journal-title":"Clin Ther"},{"key":"10.2515\/therapie\/2010051_bb0365","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/pds.1092","article-title":"Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims","volume":"14","author":"Lambert","year":"2005","journal-title":"Pharmacoepidemiol Drug Safe"},{"key":"10.2515\/therapie\/2010051_bb0370","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4088\/JCP.v63n0509","article-title":"A retrospective comparison of weight, lipid, and glucose changes between risperidone and olanzapine-treated inpatients: metabolic outcomes after 1 year","volume":"63","author":"Meyer","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.2515\/therapie\/2010051_bb0375","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1358\/mf.2005.27.5.908643","article-title":"Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes","volume":"27","author":"Silvestre","year":"2005","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.2515\/therapie\/2010051_bb0380","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejphar.2003.08.100","article-title":"Reduced dopaminergic tone in hypothalamic neural circuits: expression of a \"thrifty\" genotype underlying the metabolic syndrome?","volume":"480","author":"Pijl","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.2515\/therapie\/2010051_bb0385","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0006-3223(98)00100-0","article-title":"Novel antipsychotics and new onset diabetes","volume":"44","author":"Wirshing","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.2515\/therapie\/2010051_bb0390","doi-asserted-by":"crossref","first-page":"S335","DOI":"10.1016\/S0924-9338(05)80187-7","article-title":"Schizophrenia, antipsychotics and diabetes: genetic aspects","volume":"20","author":"Bellivier","year":"2005","journal-title":"Eur Psychiatry"},{"key":"10.2515\/therapie\/2010051_bb0395","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/01.psy.0000174994.91245.34","article-title":"Antagonism of the serotonin (5-HT)-2 receptor and insulin sensitivity: implications for atypical antipsychotics","volume":"67","author":"Gilles","year":"2005","journal-title":"Psychosom Med"},{"key":"10.2515\/therapie\/2010051_bb0400","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.cmet.2007.10.008","article-title":"Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways","volume":"6","author":"Zhou","year":"2007","journal-title":"Cell Metab"},{"key":"10.2515\/therapie\/2010051_bb0405","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2133\/dmpk.20.368","article-title":"Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus","volume":"20","author":"Matsui-Sakata","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.2515\/therapie\/2010051_bb0410","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00125-007-0696-y","article-title":"Stimulation of glycogen synthesis and inactivation of phosphorylase in hepatocytes by serotonergic mechanisms, and counter-regulation by atypical antipsychotic drugs","volume":"50","author":"Hampson","year":"2007","journal-title":"Diabetologia"},{"key":"10.2515\/therapie\/2010051_bb0415","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.pnpbp.2003.09.010","article-title":"Serotonin receptors: their key role in drugs to treat schizophrenia","volume":"27","author":"Meltzer","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.2515\/therapie\/2010051_bb0420","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.4088\/JCP.v64n1206","article-title":"Olanzapine induces insulin resistance: results from a prospective study","volume":"64","author":"Ebenbichler","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.2515\/therapie\/2010051_bb0425","doi-asserted-by":"crossref","first-page":"504","DOI":"10.4088\/JCP.v66n0414","article-title":"Atypical antipsychotics and glucose homeostasis","volume":"66","author":"Bergman","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.2515\/therapie\/2010051_bb0430","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/sj.mp.4001729","article-title":"Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells","volume":"10","author":"Engl","year":"2005","journal-title":"Mol Psychiatry"},{"key":"10.2515\/therapie\/2010051_bb0435","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jpsychires.2005.04.016","article-title":"Effects of different antipsychotics and the antidepressant mirtazapine on glucose transporter mRNA levels in human blood cells","volume":"40","author":"Heiser","year":"2006","journal-title":"J Psychiatr Res"},{"key":"10.2515\/therapie\/2010051_bb0440","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.schres.2008.04.017","article-title":"Glucose abnormalities in the siblings of people with schizophrenia","volume":"103","author":"Fernandez-Egea","year":"2008","journal-title":"Schizophr Res"},{"key":"10.2515\/therapie\/2010051_bb0445","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ejcts.2008.01.050","article-title":"Post-transplant diabetes mellitus in lung transplant recipients: incidence and risk factors","volume":"33","author":"Ollech","year":"2008","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.2515\/therapie\/2010051_bb0450","first-page":"1289","article-title":"Posttransplant diabetes mellitus-a review","volume":"58","author":"Jindal","year":"1994","journal-title":"Transplantation"},{"key":"10.2515\/therapie\/2010051_bb0455","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00007890-200202150-00011","article-title":"Posttransplant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management","volume":"73","author":"First","year":"2002","journal-title":"Transplantation"},{"key":"10.2515\/therapie\/2010051_bb0460","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0168-8278(96)80329-1","article-title":"Diabetes mellitus after liver transplantation: prevalence and predictive factors","volume":"25","author":"Navasa","year":"1996","journal-title":"J Hepat"},{"key":"10.2515\/therapie\/2010051_bb0465","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1055\/s-2000-8136","article-title":"Liver transplantation and diabetes mellitus","volume":"108","author":"Steinm\u00fcller","year":"2000","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.2515\/therapie\/2010051_bb0470","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1432-2277.2000.tb01040.x","article-title":"Treatment of tacrolimus-related adverse effects by conversion to ciclosporine in liver transplant recipients","volume":"13","author":"Emre","year":"2000","journal-title":"Transpl Int"},{"key":"10.2515\/therapie\/2010051_bb0475","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00296-008-0833-z","article-title":"Single center prospective study of tacrolimus efficacy and safety in treatment of rheumatoid arthritis","volume":"29","author":"Suzuki","year":"2009","journal-title":"Rheumatol Int"},{"key":"10.2515\/therapie\/2010051_bb0480","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.transproceed.2008.03.018","article-title":"Posttransplant diabetes mellitus and risk factors","volume":"40","author":"Mazali","year":"2008","journal-title":"Transplant Proc"},{"issue":"7","key":"10.2515\/therapie\/2010051_bb0485","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/j.1432-2277.2009.00849.x","article-title":"Tacrolimus and angiotensin receptor blockers associated with changes in serum adiponectin level in newonset diabetes after renal transplantation: single-center cross-sectional analysis","volume":"22","author":"Nishimura","year":"2009","journal-title":"Transpl Int"},{"key":"10.2515\/therapie\/2010051_bb0490","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(67)92470-1","article-title":"Glucose tolerance in hypertensive patients on long-term diuretic therapy","volume":"1","author":"Breckenridge","year":"1967","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2010051_bb0495","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2165\/00003495-198427050-00004","article-title":"Effects of antihypertensive drugs on endocrine function","volume":"27","author":"Brass","year":"1984","journal-title":"Drugs"},{"key":"10.2515\/therapie\/2010051_bb0500","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/01.HYP.7.6.1008","article-title":"Propranolol or hydrochlorothiazide alone for the initial treatment of hypertension. IV. Effect on plasma glucose and glucose tolerance. Veterans Administration Cooperative Study Group on Antihypertensive Agents","volume":"7","author":"No authors listed","year":"1985","journal-title":"Hypertension"},{"key":"10.2515\/therapie\/2010051_bb0505","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.jacc.2008.10.037","article-title":"Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum","volume":"53","author":"Cooper-De Hoff","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.2515\/therapie\/2010051_bb0510","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200003303421301","article-title":"Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis risk in communities study","volume":"342","author":"Gress","year":"2000","journal-title":"N Engl J Med"},{"key":"10.2515\/therapie\/2010051_bb0515","first-page":"S50","article-title":"Clinical significance of the metabolic effects of antihypertensive drugs","volume":"1","author":"Moser","year":"1993","journal-title":"J Hum Hypertens"},{"key":"10.2515\/therapie\/2010051_bb0520","first-page":"257","article-title":"Diabetes mellitus in treated hypertension: incidence, predictive factors and the impact of non-selective beta-blockers and thiazide diuretics during 15 years treatment of middleaged hypertensive men in the Primary Prevention Trial G\u00f6teborg, Sweden","volume":"8","author":"Samuelsson","year":"1994","journal-title":"J Hum Hypertens"},{"key":"10.2515\/therapie\/2010051_bb0525","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/sj.ki.5002564","article-title":"Thiazide-induced subtle renal injury not observed in states of equivalent hypokalemia","volume":"72","author":"Reungjui","year":"2007","journal-title":"Kidney Int"},{"key":"10.2515\/therapie\/2010051_bb0530","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1161\/01.HYP.0000231552.10054.aa","article-title":"Thiazide diuretics, potassium, and the development of diabetes: a quantitative review","volume":"48","author":"Zillich","year":"2006","journal-title":"Hypertension"},{"key":"10.2515\/therapie\/2010051_bb0535","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2337\/diab.32.2.106","article-title":"Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium","volume":"32","author":"Helderman","year":"1983","journal-title":"Diabetes"},{"key":"10.2515\/therapie\/2010051_bb0540","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1681\/ASN.2007040416","article-title":"Thiazide diuretics exacerbate fructoseinduced metabolic syndrome","volume":"18","author":"Reungjui","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.2515\/therapie\/2010051_bb0545","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s11906-003-0065-2","article-title":"The effect of aldosterone on glucose metabolism","volume":"5","author":"Corry","year":"2003","journal-title":"Curr Hypertens Rep"},{"key":"10.2515\/therapie\/2010051_bb0550","first-page":"2587","article-title":"Are thiazides diabetogenic?","volume":"113","author":"Nguyen","year":"1993","journal-title":"Tidsskr Nor Laegeforen"},{"key":"10.2515\/therapie\/2010051_bb0555","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1136\/bmj.300.6730.975","article-title":"Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects","volume":"300","author":"Carlsen","year":"1990","journal-title":"BMJ"},{"key":"10.2515\/therapie\/2010051_bb0560","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1559-4564.2007.888142.x","article-title":"Treatment of hypertension with thiazides: benefit or damage-effect of low- and high-dose thiazide diuretics on arterial elasticity and metabolic parameters in hypertensive patients with and without glucose intolerance","volume":"2","author":"Shargorodsky","year":"2007","journal-title":"J Cardiometab Syndr"},{"key":"10.2515\/therapie\/2010051_bb0565","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/ajh.2008.17","article-title":"New onset diabetes during antihypertensive therapy","volume":"21","author":"Alderman","year":"2008","journal-title":"Am J Hypertens"},{"key":"10.2515\/therapie\/2010051_bb0570","first-page":"48","article-title":"ADOPT study: which first-line glucose-lowering oral medication in type 2 diabetes?","volume":"62","author":"Scheen","year":"2007","journal-title":"Rev Med Liege"},{"key":"10.2515\/therapie\/2010051_bb0575","first-page":"853","article-title":"Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms","volume":"25","author":"Ko","year":"1997","journal-title":"Drug Metab Dispos."},{"key":"10.2515\/therapie\/2010051_bb0580","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/00498250410001685728","article-title":"Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate","volume":"34","author":"Naritomi","year":"2004","journal-title":"Xenobiotica"},{"key":"10.2515\/therapie\/2010051_bb0585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00498250110035615","article-title":"Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole","volume":"31","author":"Furuta","year":"2001","journal-title":"Xenobiotica"},{"key":"10.2515\/therapie\/2010051_bb0590","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/0006-2952(83)90415-X","article-title":"Acetaminophen-induced hepatic glycogen depletion and hyperglycemia in mice","volume":"32","author":"Hinson","year":"1983","journal-title":"Biochem Pharmacol"},{"key":"10.2515\/therapie\/2010051_bb0595","first-page":"259","article-title":"Apparent hyperglycaemia in paracetamol overdose","volume":"42","author":"Copland","year":"1992","journal-title":"Br J Gen Pract"},{"key":"10.2515\/therapie\/2010051_bb0600","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/pgmj.71.841.702","article-title":"Hyperglycaemia induced by paracetamol","volume":"71","author":"Lawrence","year":"1995","journal-title":"Postgrad Med J"},{"key":"10.2515\/therapie\/2010051_bb0605","first-page":"29","article-title":"Effects of beta-blocking agents on insulin secretion and glucose disposal","volume":"22","author":"Wicklmayr","year":"1990","journal-title":"Horm Metab Res Suppl"},{"key":"10.2515\/therapie\/2010051_bb0610","first-page":"123","article-title":"M\u00e9dications cardio-vasculaires et respiratoires. \u03b2-bloquants et agents bradycardisants. \u00c9ditions Hermann","author":"Lechat","year":"1998","journal-title":"\u00c9diteurs des sciences et des arts"},{"key":"10.2515\/therapie\/2010051_bb0615","first-page":"152","article-title":"Pharmacologie : gare au mirage de la \u00ab s\u00e9lectivit\u00e9 \u00bb !","volume":"23","author":"Montastruc","year":"2003","journal-title":"Rev Prescrire"},{"key":"10.2515\/therapie\/2010051_bb0620","first-page":"397","article-title":"A metabolic assessment of the beta 1 selectivity of bisoprolol","volume":"6","author":"Haffner","year":"1992","journal-title":"J Hum Hypertens"},{"key":"10.2515\/therapie\/2010051_bb0625","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s00392-007-0571-3","article-title":"Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure","volume":"97","author":"Kovaci\u00e6","year":"2008","journal-title":"Clin Res Cardiol"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716307053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716307053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T07:39:32Z","timestamp":1554277172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716307053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":125,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0040595716307053"],"URL":"https:\/\/doi.org\/10.2515\/therapie\/2010051","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}